var data={"title":"Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5950?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information&quot;</a> and <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154885\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bactrim;</li>\n      <li>Bactrim DS;</li>\n      <li>Sulfatrim Pediatric</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154886\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Sulfatrim;</li>\n      <li>Apo-Sulfatrim DS;</li>\n      <li>Apo-Sulfatrim Pediatric;</li>\n      <li>Protrin DF;</li>\n      <li>Septra Injection;</li>\n      <li>Teva-Trimel;</li>\n      <li>Teva-Trimel DS;</li>\n      <li>Trisulfa;</li>\n      <li>Trisulfa DS;</li>\n      <li>Trisulfa S</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154907\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Miscellaneous;</li>\n      <li>\n        Antibiotic, Sulfonamide Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154889\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Weight-based dosing recommendations are based on the trimethoprim (TMP) component. Each <b>double-strength</b> tablet contains TMP 160 mg and sulfamethoxazole (SMX) 800 mg. Each <b>single-strength</b> tablet contains TMP 80 mg and SMX 400 mg. The undiluted IV solution contains TMP 16 mg per mL and SMX 80 mg per mL. IV solutions must be diluted in D5W prior to use. Diluted IV solutions have limited stability and can precipitate unpredictably; refer to a detailed IV compatibility reference.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing guidelines:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 1 to 2 double-strength tablets every 12 to 24 hours. <b>Note:</b> Serum creatinine and potassium concentrations should be monitored in outpatients receiving high-dose therapy (&gt;5 mg/kg TMP component/day) (Gentry 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 8 to 20 mg (TMP component)/kg/day divided every 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wound infections, prophylaxis or treatment (animal, human; alternative agent) (off-label use):</b> Oral: One double-strength tablet twice daily; in combination with an appropriate agent for anaerobic coverage. Duration of treatment for prophylaxis is 3 to 5 days; duration of treatment for established infection varies based on patient-specific factors (Harper 2017; IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brain abscess, empyema, and epidural abscess (alternative agent for MRSA) (off-label use):</b> IV: 5 mg (TMP component)/kg/<b>dose</b> every 8 to 12 hours (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic obstructive pulmonary disease, acute exacerbations; uncomplicated (alternative agent; outpatient therapy):</b> Oral: One double-strength tablet every 12 hours for 5 to 7 days (Bartlett 2017; GOLD 2017; Snow 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic foot infection, mild (MRSA) (off-label use): </b>Oral: Two double-strength tablets twice daily, usually for 1 to 2 weeks (IDSA [Lipsky 2012]; Lipsky 2004).<b> Note:</b> When used as empiric therapy, must be used in combination with other appropriate agents. Some experts also use this agent for selected moderate infections (Lipsky 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diarrhea, infectious:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cyclosporiasis (off-label use):</i> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompromised (AIDS<i>-</i>associated): Limited data available: One double-strength tablet twice daily for 14 days, followed by secondary prophylaxis with one double-strength tablet 3 times weekly (Pape 1994; Weller 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompetent: One double-strength tablet twice daily for 7 to 10 days (CDC 2017; Hoge 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cystoisosporiasis (isosporiasis) (off-label use):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompromised (AIDS-associated): Oral, IV: 160 mg (TMP component) twice daily for 7 to 10 days; if symptoms worsen or persist, may increase dose to 160 mg (TMP component) 4 times daily and/or prolong duration to 21 to 28 days. In patients with CD4 &lt;200 cells/mm<sup>3</sup>, follow treatment with secondary prophylaxis of one double-strength tablet orally 3 times weekly (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompetent (usually self-limited; treatment not always indicated): Oral: One double-strength tablet twice daily for 7 to 10 days (CDC 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Shigellosis </i>(widespread resistance [alternative agent if susceptibility is documented]): Oral: One double strength tablet twice daily for 5 to 7 days (Agha 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Granuloma inguinale (Donovanosis) (alternative agent) (off-label use):</b> Oral: One double-strength tablet every 12 hours for at least 3 weeks and until lesions have healed (CDC [Workowski 2015]). <b>Note: </b>If symptoms do not improve within the first few days of therapy, another agent (eg, aminoglycoside) can be added (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melioidosis (</b>\n      <i>\n        <b>Burkholderia pseudomallei</b></i>\n      <b>) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial intensive therapy (as a potential add-on to primary therapy [ceftazidime or a carbapenem] in focal disease of the CNS, prostate, bone, or other deep-seated infection) (Cheng 2009; Lipsitz 2012): </i>Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">40 to 60 kg: 240 mg (TMP component) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;60 kg: 320 mg (TMP component) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Eradication therapy (begin after completion of initial intensive therapy) (Cheng 2009; Lipsitz 2012):</i> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">40 to 60 kg: 240 mg (TMP component) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;60 kg: 320 mg (TMP component) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis, bacterial (alternative agent for MRSA, <i>L. monocytogenes</i>, <i>E. coli</i>, and other Enterobacteriaceae) (off-label use):</b> IV: 5 mg (TMP component)/kg/<b>dose</b> every 6 to 12 hours (IDSA [Tunkel 2004; Tunkel 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative dosing for MRSA meningitis:</i> 5 mg (TMP component)/kg/dose every 8 to 12 hours (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nocardiosis (off-label use):</b> Limited data available to guide treatment. Due to concerns for resistance, susceptibility testing should be performed on isolates (CDC 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cutaneous infections (superficial; no other organ involvement): Oral: 5 to 10 mg (TMP component)/kg/day in 2 divided doses (Spelman 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pulmonary infection (mild to moderate) (Spelman 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompetent patients: Oral: 5 to 10 mg (TMP component)/kg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompromised patients: IV: 15 mg (TMP component)/kg/day in 3 to 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pulmonary infection (severe), CNS, disseminated, or multi-site infection: IV: 15 mg (TMP component)/kg/day in 3 to 4 divided doses (Spelman 2017). <b>Note:</b> When used as empiric therapy, must be used in combination with 1 to 2 additional agents. Consult an infectious diseases specialist for specific treatment recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duration: Prolonged treatment is required (range: 3 months to &ge;1 year [combined parenteral/oral therapy]) (Spelman 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis due to MRSA (alternative agent; off-label use):</b> Oral, IV: 4 mg (TMP component)/kg/<b>dose</b> every 12 hours with rifampin (Lalani 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peritonitis, spontaneous bacterial (prevention) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>High-risk patients (eg, hospitalized patients with Child-Pugh class B or C cirrhosis and active GI bleeding)</i>: Oral: One double-strength tablet twice daily (Runyon 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Long-term secondary SBP prophylaxis</i>: Oral: One double-strength tablet once daily (Runyon 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Pneumocystis</b></i>\n      <b> pneumonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylaxis, primary and secondary (off-label dose): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-infected: Oral: One double-strength tablet once daily <b>or</b> one single-strength tablet once daily (preferred regimens) <b>or</b> one double-strength tablet three times weekly (alternative regimen). <b>Note:</b> In patients also requiring prophylaxis for toxoplasmosis, one double-strength tablet once daily should be used (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">\n      <i>Duration in HIV-infected patients receiving ART:</i> Continue until undetectable viral load and CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months (HHS [Adult OI 2017]); some experts discontinue primary prophylaxis in patients with CD4 counts between 100 and 200 cells/mm<sup>3</sup> who are receiving ART and have had an undetectable viral load for &ge;3 to 6 months (HHS [OI adult 2017]; COHERE 2010) or &ge;12 months (Sax 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompromised host, HIV-uninfected (eg, transplant recipients, cancer-related, hematopoietic stem cell transplant [HCT]) (off-label dose): Oral: One double-strength tablet once daily <b>or </b>one single-strength tablet once daily (preferred regimens); alternatively one double strength tablet three times weekly (Fishman 2001; Montoya 2001; Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Duration after solid organ transplantation (except lung):</i> &ge;6 to 12 months and during periods of increased immunosuppression (eg, treatment for acute rejection) (Alexander 2017; Martin 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Duration after lung transplantation:</i> Lifelong therapy should be considered (Palmer 2017; Martin 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Duration for cancer-related (including HSCT) high risk for PCP infection: </i>Based on expert opinion, continue until risk factor(s) for PCP infection are no longer present (Neumann 2013, Thomas 2017). Consult other specialized databases for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment </i>(off-label dose; HHS [OI adult 2017]; ATS [Limper 2011]; Thomas 2017)<i>: </i><b>Note: </b>Secondary prophylaxis should be initiated immediately upon completion of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate to severe infection: IV: 15 to 20 mg (TMP component)/kg/day in 3 or 4 divided doses for 21 days; may switch to oral therapy after clinical improvement.<b> Note:</b> Patients with moderate or severe infection (PaO<sub>2</sub> &lt;70 mm Hg at room air or alveolar-arterial oxygen gradient &ge;35 mm Hg) should receive adjunctive glucocorticoids.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection: Oral: 15 to 20 mg (TMP component)/kg/day in 3 divided doses for 21 days <b>or</b> two double-strength tablets three times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection (off-label use):</b> Treatment (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Duration of therapy ranges from a minimum of 3 months to indefinitely, depending on patient specific factors (Berbari 2018)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Staphylococci</i> (methicillin-resistant) and <i>Enterobacteriaceae</i>: One double-strength tablet twice daily. For the first 3 to 6 months of therapy for staphylococcal infections, combine with rifampin (Berbari 2018; IDSA [Osmon 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Q fever (<i>C. burnetii</i>) (preferred agent for pregnant women &le;32 weeks of gestation; alternative agent for non-pregnant adults) (off-label use):</b> Oral: <i>Acute illness:</i> One double strength tablet twice daily during pregnancy but not beyond 32 weeks' gestation; administer with folic acid supplementation. <b>Note:</b> Discontinue therapy for the final 8 weeks of pregnancy due to hyperbilirubinemia risk (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic arthritis (without prosthetic material) due to MRSA (alternative agent following initial IV therapy with an appropriate antibiotic) (off-label use):</b> Oral: Two double-strength tablets twice daily <b>or</b> 4 mg (TMP component)/kg/<b>dose</b> twice daily (maximum: 320 mg (TMP component)/<b>dose</b>) for completion of 3 to 4 week total treatment course (IV and oral) (Goldenberg 2017; IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin/soft tissue infection, mild to moderate (outpatient treatment; empiric coverage of MRSA) (off-label use):</b> Oral: One to two double-strength tablets twice daily for 5 to 10 days (IDSA [Liu 2011; Stevens 2014]). <b>Note:</b> For empiric therapy of non-purulent cellulitis, an additional agent (eg, amoxicillin, cephalexin) for beta-hemolytic streptococci coverage is needed (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Stenotrophomonas maltophilia </b></i>\n      <b>infections</b> <b>(hospital-acquired pneumonia [HAP], ventilator-associated pneumonia [VAP], bacteremia, or other sites) (off-label use):</b> IV: 15 mg (TMP component)/kg/day in 3 or 4 divided doses. Additional data may be necessary to further define the role of sulfamethoxazole/trimethoprim in this condition (Lewis 2017; Looney 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Toxoplasma gondii</b></i>\n      <b> encephalitis (AIDS-associated) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Primary prophylaxis: Oral: One double-strength tablet once daily (preferred) <b>or</b> one double-strength tablet 3 times weekly <b>or</b> one single-strength tablet once daily; primary prophylaxis is indicated for Toxoplasma IgG-positive patients with CD4 count &lt;100 cells/mm<sup>3</sup>. Continue primary prophylaxis following initiation of ART until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months; some experts discontinue primary prophylaxis in patients with a CD4 count between 100 to 200 cells/mm<sup>3</sup> who are receiving ART and have had an undetectable viral load for &ge;3 to 6 <b>months</b> (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment (alternative agent): Oral, IV: 10 mg (TMP component)/kg/day in 2 divided doses for at least 6 weeks; longer duration may be needed if clinical or radiologic disease is extensive or response is incomplete at 6 weeks (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Secondary prophylaxis (chronic maintenance therapy; alternative agent): Oral: One double-strength tablet twice daily <b>or</b>, alternatively, one double-strength tablet once daily (lower dose may be associated with increased relapse risk). Continue following initiation of ART until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;6 months (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection (off-label dose):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cystitis, acute uncomplicated (empiric use [avoid if resistance prevalence is known to exceed 20% or if used for UTI in previous 3 months] or targeted therapy [if the isolate is known to be susceptible]): Oral: One double-strength tablet twice daily for 3 days (IDSA [Gupta 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pyelonephritis, acute uncomplicated (outpatient targeted therapy [if the isolate is known to be susceptible]): Oral: One double-strength tablet twice daily for 14 days (IDSA [Gupta 2011]); for women who have a rapid response to treatment, some experts treat for 7 to 10 days (Hooton 2017)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154900\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Weight-based dosing recommendations are based on the trimethoprim (TMP) component. Each <b>double-strength</b> tablet contains TMP 160 mg and sulfamethoxazole (SMX) 800 mg. Each <b>single-strength</b> tablet contains TMP 80 mg and SMX 400 mg. The undiluted IV solution contains TMP 16 mg per mL and SMX 80 mg per mL. IV solutions must be diluted in D5W prior to use. Diluted IV solutions have limited stability and can precipitate unpredictably; refer to a detailed IV compatibility reference.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing guidelines:</b> Infants &ge;2 months of age, Children, and Adolescents: Oral, IV: 6 to 12 mg TMP/kg/day in divided doses every 12 hours; maximum single dose: 160 mg TMP/dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Indication-specific dosing: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diarrhea, infectious:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cyclosporiasis (off-label use):</i> Limited data available: Infants &ge;2 months of age, Children, and Adolescents: Immunocompetent patients: Oral: 8 to 10 mg TMP/kg/day in divided doses twice daily for 7 to 10 days; maximum single dose: 160 mg TMP (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cystoisosporiasis (isosporiasis) (AIDS-associated) (off-label use):</i> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Shigellosis: </i>Infants &ge;2 months of age, Children, and Adolescents: <b>Note:</b> Due to reported widespread resistance, empiric therapy with sulfamethoxazole and trimethoprim is not recommended (CDC-NARMS 2010; WHO 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: 8 mg TMP/kg/day in divided doses every 12 hours for 5 days; maximum single dose: 160 mg TMP</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate recommendations (off-label dose): IDSA recommendations for infectious diarrhea: 10 mg TMP/kg/day in divided doses every 12 hours for 3 days (for immunocompetent patients) or 7 to 10 days (for immunocompromised patients); maximum single dose: 160 mg TMP (Guerrant 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 8 to 10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute:</b> Infants &ge;2 months of age, Children, and Adolescents: Oral: 6 to 10 mg TMP/kg/day in divided doses every 12 hours for 10 days. <b>Note:</b> Due to resistance of <i>S. pneumoniae</i>, should not be used in patients that fail first-line amoxicillin therapy (AAP [Lieberthal 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Pneumocystis </b></i>\n      <b>pneumonia (PCP<i>)</i> (HIV-exposed/-positive) (off-label dose):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants (at least 4 weeks of age) and Children: Oral: 5 to 10 mg TMP/kg/day or 150 mg TMP/<b>m<sup>2</sup></b>/day; dose may be given as a single daily dose or in divided doses every 12 hours given 2 to 3 days per week on consecutive days or alternating days; maximum daily dose: TMP 320 mg/<b>day</b> (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Oral: 80 to 160 mg TMP daily or alternatively, 160 mg TMP 3 times weekly (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &gt;2 months of age and Children: Initial: IV: 15 to 20 mg TMP/kg/day in divided doses every 6 hours for 21 days; as acute pneumonitis subsides in patients with mild to moderate disease and no malabsorption issues nor diarrhea, may transition to oral therapy of same daily dose (15 to 20 mg/kg/day TMP) administered in divided doses 3 or 4 times daily (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents (HHS [OI adult 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild to moderate: Oral: 15 to 20 mg TMP/kg/day in 3 divided doses for 21 days <b>or</b> alternatively, 320 mg TMP 3 times daily for 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate to severe: Initial: IV: 15 to 20 mg TMP/kg/day in 3 to 4 divided doses for 21 days; may switch to oral after clinical improvement</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Q fever (<i>C. burnetii</i>); mild infection (doxycycline therapeutic failure) (off-label use): </b>Oral:<i> Acute illness: Limited data available; base dose on severity of illness: </i>Children &lt;8 years of age: 8 to 10 mg TMP/kg/day in divided doses twice daily for 14 days; a wider dose range of 4 to 20 mg TMP/kg/day divided twice daily has been suggested to address varying degrees of severity; however, reported pediatric efficacy experience (eg, case series) are lacking; monitor patients receiving doses at the high and low end of the range closely for efficacy and possible adverse effects (Bradley 2017; CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin/soft tissue infection, mild to moderate (due to MRSA; off-label use): </b>Infants &ge;2 months of age, Children, and Adolescents: Oral: 8 to 12 mg TMP/kg/day in divided doses every 12 hours (IDSA [Liu 2011]; alternatively, use of 20 mg TMP/kg/day in divided doses every 6 hours has been reported (Long 2012). <b>Note:</b> If beta-hemolytic <i>Streptococcus</i> spp. are also suspected, a beta-lactam antibiotic should be added to the regimen (IDSA [Liu 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Toxoplasmosis (HIV-exposed/-infected) (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Primary prophylaxis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;2 months of age and Children: Oral: 150 mg TMP/<b>m<sup>2</sup></b>/day; dose may be administered as a single daily dose (preferred) or in divided doses every 12 hours; alternatively may be given 3 times weekly for 3 consecutive or alternating days (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Oral: 160 mg TMP daily (preferred) <b>or</b> 160 mg TMP 3 times weekly <b>or</b> 80 mg TMP daily (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment, encephalitis (alternative agent):</i> Adolescents: Oral, IV: 10 mg/kg/day TMP in two divided doses for at least 6 weeks; longer duration may be required in some patients; following treatment all patients should receive chronic maintenance therapy daily (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Secondary prophylaxis (chronic suppressive therapy; alternative agent):</i> <b>Note: </b>Only use when pyrimethamine is unavailable or not tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: Oral: 150 mg TMP<b>/m</b><b><sup>2</sup></b>/day once daily (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: <i>Maintenance therapy; postencephalitis treatment:</i> Oral: 160 mg TMP once or twice daily: May discontinue when asymptomatic and CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;6 months in response to ART. <b>Note:</b> Once-daily dosing may be associated with an increased risk of relapse; if used, a gradual transition (eg, follow acute treatment with 4 to 6 weeks of 160 mg TMP twice daily before lowering to once-daily dosing) may be beneficial (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection (off-label dose):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children 2 to 24 months: 6 to 12 mg TMP/kg/day in divided doses every 12 hours for 7 to 14 days (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &gt;24 months of age and Adolescents: 8 mg TMP/kg/day in divided doses every 12 hours for 3 days; longer duration may be required in some patients; maximum single dose: 160 mg TMP</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Infants &ge;2 months of age, Children, and Adolescents: 8 to 10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for up to 14 days with serious infections</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis:</i> Infants &ge;2 months of age, Children, and Adolescents: Oral: 2 mg TMP/kg/dose once daily (Mattoo 2007; <i>Red Book</i> 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154890\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154891\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adults:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 15 to 30 mL/minute: Administer 50% of recommended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;15 mL/minute: Use is not recommended and is contraindicated per the manufacturer's labeling in severe renal disease if renal function cannot be monitored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Golightly 2013:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: <b>Note:</b> The following dosage adjustments are based on a usual maintenance dose of 1 double-strength tablet every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR 10 to 50 mL/minute: One double-strength tablet once, followed by 1 single-strength tablet every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &lt;10 mL/minute: Avoid use; if necessary, 1 double-strength tablet once, followed by 1 single-strength tablet every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: One double-strength tablet once, followed by 1 single-strength tablet every 24 hours (dose after hemodialysis on dialysis days)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: <b>Note:</b> The following dosage adjustments are based on a usual maintenance dose of 4 to 5 mg TMP/kg every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR 10 to 50 mL/minute: 4 to 5 mg TMP/kg every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &lt;10 mL/minute: Avoid use; if necessary, 2.5 to 5 mg TMP/kg every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: 2.5 to 5 mg TMP/kg every 24 hours (dose after hemodialysis on dialysis days)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HHS (OI adult 2016) <i>Pneumocystis</i> pneumonia (PCP), treatment: <b>Note:</b> Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: <b>Note:</b> The following dosage adjustments are based on a usual maintenance dose of 2 double-strength tablets every 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 10 to 30 mL/minute: Two double-strength tablets every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;10 mL/minute: One double-strength tablet every 12 hours <b>or</b> 2 double-strength tablets every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: 2 double-strength tablets once daily (dose after hemodialysis on dialysis days); consider therapeutic drug monitoring to optimize therapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: <b>Note:</b> The following dosage adjustments are based on a usual maintenance dose of 5 mg TMP/kg every 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 10 to 30 mL/minute: 5 mg TMP/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;10 mL/minute: 5 mg TMP/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: 5 mg TMP/kg once daily (dose after hemodialysis on dialysis days); consider therapeutic drug monitoring to optimize therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVH/CVVHD/CVVHDF: Oral, IV: 2.5 to 7.5 mg/kg of TMP every 12 hours. <b>Note:</b> Dosing regimen dependent on clinical indication. Critically ill patients with <i>P. jirovecii</i> pneumonia receiving CVVHDF may require up to 10 mg/kg every 12 hours (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Pediatric:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> Infants &ge;2 months of age, Children, and Adolescents: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;30 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 15 to 30 mL/minute: Administer 50% of recommended dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;15 mL/minute: Use is not recommended and is contraindicated per the manufacturer's labeling in severe renal disease if renal function cannot be monitored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (Veltri 2004): Oral, IV: <b>Note:</b> Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/<b>dose</b> every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 50 mL/minute/1.73 m<sup>2</sup>: 3 to 5 mg TMP/kg/<b>dose</b> every 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: 3 to 5 mg TMP/kg/<b>dose</b> every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: 3 to 5 mg TMP/kg/<b>dose</b> every 24 hours; administer 2.5 mg TMP/kg/<b>dose</b> after each dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CRRT (CAVH/CVVH/CAVHD/CVVHD):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Combined dialysis flow + ultrafiltration rate &lt;1,500 mL/m<sup>2</sup>/hour: 3 to 5 mg TMP/kg/<b>dose</b> every 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Combined dialysis flow + ultrafiltration rate &ge;1,500 mL/m<sup>2</sup>/hour: 4 to 5 mg TMP/kg/<b>dose</b> every 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Pneumocystis</i> pneumonia (PCP), treatment: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children (Veltri 2004): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 5 mg/kg/<b>dose</b> every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">CrCl 10 to 50 mL/minute/1.73 m<sup>2</sup>: 5 mg TMP/kg/<b>dose</b> every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: 5 mg TMP/kg/<b>dose</b> every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Hemodialysis: 5 mg TMP/kg/<b>dose</b> every 12 hours; administer 2.5 mg TMP/kg/<b>dose</b> after each dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">CRRT: CAVH/CVVH/CAVHD/CVVHD: 5 mg TMP/kg<b>/dose</b> every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22757570\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling. Use with caution; use is contraindicated in cases of marked hepatic damage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154857\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Sulfamethoxazole 80 mg and trimethoprim 16 mg per mL (5 mL, 10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sulfatrim Pediatric: Sulfamethoxazole 200 mg and trimethoprim 40 mg per 5 mL (473 mL) [contains alcohol, usp, fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow), methylparaben, polysorbate 80, propylene glycol, propylparaben, saccharin sodium; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Sulfamethoxazole 200 mg and trimethoprim 40 mg per 5 mL (20 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bactrim: Sulfamethoxazole 400 mg and trimethoprim 80 mg [scored; contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bactrim DS: Sulfamethoxazole 800 mg and trimethoprim 160 mg [scored; contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Sulfamethoxazole 400 mg and trimethoprim 80 mg, Sulfamethoxazole 800 mg and trimethoprim 160 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154842\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45703744\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The 5:1 ratio (SMX:TMP) remains constant in all dosage forms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50148639\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, Oral: Sulfamethoxazole 100 mg and trimethoprim 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154861\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse diluted solution over 60-90 minutes; not for IM injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer without regard to meals. Administer with at least 8 ounces of water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154860\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment of urinary tract infections due to <i>Escherichia</i><i> coli</i>, <i>Klebsiella</i> and <i>Enterobacter</i> spp, <i>Morganella</i><i> morganii</i>, <i>Proteus</i><i> mirabilis</i> and <i>Proteus</i><i> vulgaris</i>; acute otitis media; acute exacerbations of COPD due to susceptible strains of <i>Haemophilus</i><i> influenzae</i> or <i>Streptococcus</i><i> pneumoniae</i>; treatment and prophylaxis of <i>Pneumocystis</i> pneumonia (PCP); traveler's diarrhea due to enterotoxigenic <i>E. coli</i>; treatment of Shigellosis caused by <i>Shigella flexneri</i> or <i>Shigella sonnei</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Treatment of <i>Pneumocystis </i>pneumonia (PCP); treatment of Shigellosis caused by <i>Shigella flexneri</i> or <i>Shigella sonnei</i>; treatment of severe or complicated UTIs due to <i>E. coli, Klebsiella</i> and <i>Enterobacter</i> spp, <i>M. morganii, P. mirabilis,</i> and <i>P. vulgaris</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470631\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bite wound infections (animal and human bites); Brain abscess, empyema, and epidural abscess (methicillin-resistant Staphylococcus aureus); Cyclosporiasis; Cystoisosporiasis (Isosporiasis); Diabetic foot infection; Granuloma inguinale (Donovanosis); Head lice (Pediculosis capitis); Melioidosis (Burkholderia pseudomallei) infection; Meningitis, bacterial; Nocardiosis; Osteomyelitis; Peritonitis, spontaneous bacterial (prevention); Prosthetic joint infection; Q Fever (Coxiella burnetii); Septic arthritis (methicillin-resistant Staphylococcus aureus); Skin and soft tissue infections (methicillin-resistant Staphylococcus aureus); Stenotrophomonas maltophilia infections; Toxoplasma gondii encephalitis (prophylaxis/treatment/chronic maintenance) in HIV-infected patients (adolescents and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154917\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bactrim may be confused with bacitracin, Bactine, Bactroban</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Co-trimoxazole may be confused with clotrimazole </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Septra may be confused with Ceptaz, Sectral</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Septra DS may be confused with Semprex-D</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154849\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Allergic myocarditis, periarteritis nodosa (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Apathy, aseptic meningitis, ataxia, chills, depression, fatigue, hallucination, headache, insomnia, nervousness, peripheral neuritis, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema multiforme (rare), exfoliative dermatitis (rare), pruritus, skin photosensitivity, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperkalemia (generally at high dosages), hypoglycemia (rare), hyponatremia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, glottis edema, kernicterus (in neonates), nausea, pancreatitis, pseudomembranous colitis, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Crystalluria, diuresis (rare), nephrotoxicity (in association with cyclosporine), toxic nephrosis (with anuria and oliguria)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anaphylactoid purpura (IgA vasculitis; rare), aplastic anemia, eosinophilia, hemolysis (with G6PD deficiency), hemolytic anemia, hypoprothrombinemia, leukopenia, megaloblastic anemia, methemoglobinemia, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic jaundice, hepatotoxicity (including hepatitis, cholestasis, and hepatic necrosis), hyperbilirubinemia, increased transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction, serum sickness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, rhabdomyolysis (mainly in AIDS patients), systemic lupus erythematosus (rare), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctival injection, injected sclera</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, interstitial nephritis, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, pulmonary infiltrates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing: Dysgeusia (Syed 2016), immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura), prolonged Q-T interval on ECG, thrombotic thrombocytopenic purpura</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154864\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to any sulfa drug, trimethoprim, or any component of the formulation; history of drug induced-immune thrombocytopenia with use of sulfonamides or trimethoprim; megaloblastic anemia due to folate deficiency; infants &lt;2 months (manufacturer's labeling), infants &lt;4 weeks (CDC 2009); marked hepatic damage or severe renal disease (if patient not monitored); concomitant administration with dofetilide</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although the FDA approved product labeling states this medication is contraindicated with other sulfonamide-containing drug classes, the scientific basis of this statement has been challenged. See &ldquo;Warnings/Precautions&rdquo; for more detail.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Blood dyscrasias; pregnancy; breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154846\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Fatalities associated with severe reactions including agranulocytosis, aplastic anemia, and other blood dyscrasias have occurred; discontinue use at first sign of rash or signs of serious adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Fatalities associated with severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred; discontinue use at first sign of rash.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic necrosis: Fatalities associated with hepatic necrosis have occurred; discontinue use at first sign of rash or signs of serious adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: May cause hyperkalemia; potential risk factors for trimethoprim-induced hyperkalemia include high dosage (20 mg/kg/day of trimethoprim), renal impairment, older age, hypoaldosteronism, and concomitant use of medications causing or exacerbating hyperkalemia (Perazella 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: May cause hypoglycemia, particularly in malnourished, or patients with renal or hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyponatremia: Severe and symptomatic hyponatremia may occur, particularly in patients treated for <i>Pneumocystis jirovecii</i> pneumonia (PCP).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfonamide (&ldquo;sulfa&rdquo;) allergy: Traditionally, concerns for cross-reactivity have extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur, or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides. A nonantibiotic sulfonamide compound which contains the arylamine structure and therefore may cross-react with antibiotic sulfonamides is sulfasalazine (Zawodniak 2010). T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: Immune mediated thrombocytopenia may occur. Severe cases which may be life-threatening or fatal have been reported. Thrombocytopenia usually resolves within 1 week following discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma/allergies: Use with caution in patients with allergies or asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended. Maintain adequate hydration to prevent crystalluria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leucovorin: Avoid concomitant use when treating <i>Pneumocystis jirovecii</i> pneumonia (PCP) in HIV patients; may increase risk of treatment failure and death.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; AIDS patients: Incidence of adverse effects appears to be increased in patients with AIDS.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; greater risk for more severe adverse reactions, including hyperkalemia associated with trimethoprim use. Elderly patients are at an increased risk for severe and potentially life-threatening hyperkalemia when trimethoprim is used concomitantly with medications known to cause or exacerbate hyperkalemia, such as spironolactone, ACE inhibitors, or ARBs (Antoniou 2010; Antoniou 2011; Antoniou, 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: Use with caution in patients with G6PD deficiency; hemolysis may occur (dose-related).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients with potential for folate deficiency: Use with caution in patients with potential folate deficiency (malnourished, chronic anticonvulsant therapy, or elderly).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porphyria: Use with caution in patients with porphyria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnant women: Use during pregnancy may be associated with embryo-fetal toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Slow acetylators: May be more prone to adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP [&quot;Inactive&quot; 1997]; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfite sensitivity: Injection may contain sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible persons. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic persons.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: When used for uncomplicated urinary tract infections, this combination should not be used if a single agent is effective. Additionally, sulfonamides should not be used to treat group A beta-hemolytic streptococcal infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154902\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154851\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9785&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amodiaquine: Trimethoprim may enhance the neutropenic effect of Amodiaquine. Trimethoprim may increase the serum concentration of Amodiaquine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Trimethoprim may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Sulfamethoxazole may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May diminish the therapeutic effect of Sulfonamide Antibiotics. Management: Avoid concurrent use of chloroprocaine and systemic sulfonamide-based antimicrobials whenever possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Sulfonamide Antibiotics may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Antibiotics may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Systemic): Trimethoprim may increase the serum concentration of Dapsone (Systemic). Dapsone (Systemic) may increase the serum concentration of Trimethoprim. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): Trimethoprim may enhance the adverse/toxic effect of Dapsone (Topical). More specifically, trimethoprim may increase the risk for hemolysis <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Trimethoprim may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: Trimethoprim may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Trimethoprim may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Fosphenytoin. Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamiVUDine: Trimethoprim may increase the serum concentration of LamiVUDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for <i>Pneumocystis jirovecii</i> pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Trimethoprim may increase the serum concentration of Memantine. Memantine may increase the serum concentration of Trimethoprim. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: Sulfamethoxazole may enhance the myelosuppressive effect of Mercaptopurine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Trimethoprim may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: May enhance the adverse/toxic effect of Sulfonamide Antibiotics. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Trimethoprim may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Trimethoprim may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Trimethoprim.  Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Sulfamethoxazole may increase the serum concentration of Phenytoin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Antibiotics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Sulfamethoxazole may increase the serum concentration of PRALAtrexate. More specifically, sulfamethoxazole may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of sulfamethoxazole. Monitor for decreased pralatrexate levels with discontinuation of sulfamethoxazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procaine: May diminish the therapeutic effect of Sulfonamide Antibiotics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyrimethamine: May enhance the adverse/toxic effect of Trimethoprim.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: Trimethoprim may decrease the metabolism of Repaglinide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: Trimethoprim may enhance the hyperkalemic effect of Spironolactone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Sulfonamide Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazolidinediones: Trimethoprim may decrease the metabolism of Thiazolidinediones. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Trimethoprim may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Sulfonamide Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154854\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154867\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. Sulfamethoxazole and trimethoprim cross the placenta and distribute to amniotic fluid (Ylikorkala, 1973). An increased risk of congenital malformations (neural tube defects, cardiovascular malformations, urinary tract defects, oral clefts, club foot) following maternal use of sulfamethoxazole and trimethoprim during pregnancy has been observed in some studies. Folic acid supplementation may decrease this risk (Crider 2009; Czeizel 2001; Hernandez-Diaz 2000; Hernandez-Diaz 2001; Matok 2009). Due to theoretical concerns that sulfonamides pass the placenta and may cause kernicterus in the newborn, neonatal healthcare providers should be informed if maternal sulfonamide therapy is used near the time of delivery (DHHS 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The pharmacokinetics of sulfamethoxazole and trimethoprim are similar to nonpregnant values in early pregnancy (Ylikorkala 1973). Sulfamethoxazole and trimethoprim are recommended for the prophylaxis or treatment of <i>Pneumocystis jirovecii</i> pneumonia (PCP), prophylaxis of <i>Toxoplasmic gondii</i> encephalitis (TE), and for the acute and chronic treatment of Q fever in pregnancy (CDC 2013; DHHS 2013). Sulfonamides may also be used to treat other infections in pregnant women when clinically appropriate; use during the first trimester should be limited to situations where no alternative therapies are available (ACOG 2011). Because safer options are available for the treatment of urinary tract infections in pregnant women, use of TMP-containing products in the first trimester and sulfonamide-containing products &gt;32 weeks gestation should be avoided (Lee 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154868\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfamethoxazole and trimethoprim are excreted in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The manufacturer states that the exposure of sulfamethoxazole and trimethoprim to the breastfeeding infant would be 2% to 5% of the recommended daily dose for infants &gt;2 months of age (maternal dose, milk concentration, and infant dose not specified). The relative infant dose (RID) of trimethoprim is 3% when compared to an infant therapeutic trimethoprim dose of 10 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000). Using an average trimethoprim milk concentration of 2 mcg/mL, the estimated daily infant trimethoprim dose via breast milk would be &lt;0.3 mg/kg/day; using an average sulfamethoxazole milk concentration of 5.34 mcg/mL, the estimated daily infant sulfamethoxazole dose via breast milk would be &lt;0.8 mg/kg/day. These milk concentrations were obtained following a maternal dose of trimethoprim 80 mg-sulfamethoxazole 400 mg as either 2 tablets (n=40) or 3 tablets (n=10) twice daily for a minimum of 5 days (Miller 1974).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The therapeutic use of sulfamethoxazole and trimethoprim is contraindicated in infants &lt;2 months of age due to the possibility of bilirubin displacement resulting in kernicterus and hemolytic anemia caused by immature erythrocyte enzyme systems; theoretically, the risk of kernicterus and hemolytic anemia is present in breastfed infants exposed to sulfamethoxazole and trimethoprim via breast milk (Mitrano 2009). The manufacturer recommends that caution be used if administered to nursing women, especially if breastfeeding infants that are ill, jaundiced, premature, or stressed due to the potential risk of bilirubin displacement and kernicterus. Avoid use of sulfamethoxazole in women who are breastfeeding an infant with G6PD deficiency (WHO 2002) or hyperbilirubinemia (Della-Giustina 2003). The WHO considers sulfamethoxazole and trimethoprim compatible with breastfeeding in older, healthy, full-term infants with monitoring of the infant for jaundice and hemolysis (WHO 2002). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154869\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Should be taken with 8 oz of water. May be taken without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6059143\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, serum potassium, creatinine, BUN</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154845\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sulfamethoxazole interferes with bacterial folic acid synthesis and growth via inhibition of dihydrofolic acid formation from para-aminobenzoic acid; trimethoprim inhibits dihydrofolic acid reduction to tetrahydrofolate resulting in sequential inhibition of enzymes of the folic acid pathway</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154863\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid; almost completely (90% to 100%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Both SMX and TMP distribute to middle ear fluid, sputum, vaginal fluid; TMP also distributes into bronchial secretions</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: TMP:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Newborns: ~2.7 L/kg (range: 1.3 to 4.1 hours) (Springer 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants: 1.5 L/kg (Hoppu 1989) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to 10 years: 0.86 to 1 L/kg (Hoppu 1987) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: ~1.3 L/kg (Hoppu 1987) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: SMX:  ~70%, TMP: ~44% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, both to multiple metabolites; SMX to hydroxy  (via CYP2C9) and acetyl derivatives, and also conjugated with glucuronide; TMP to oxide and hydroxy derivatives; the free forms of both SMX and TMP are therapeutically active </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TMP: Prolonged in renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Newborns: ~19 hours; range: 11 to 27 hours (Springer 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 2 months to 1 year: ~4.6 hours; range: 3 to 6 hours (Hoppu 1989) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to 10 years: 3.7 to 5.5 hours (Hoppu 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents &gt;10 years: 8.19 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 6 to 11 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SMX: 9 to 12 hours, prolonged in renal failure </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 1 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Both are excreted in urine as metabolites and unchanged drug </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154866\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sulfamethoxazole-Trimethoprim Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400-80 mg/5 mL (5 mL): $7.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Sulfamethoxazole-Trimethoprim Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200-40 mg/5 mL (473 mL): $215.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Sulfatrim Pediatric Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200-40 mg/5 mL (473 mL): $112.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bactrim DS Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800-160 mg (100): $311.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bactrim Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400-80 mg (100): $172.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sulfamethoxazole-Trimethoprim Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400-80 mg (100): $66.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800-160 mg (100): $115.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154870\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abacin (IT);</li>\n      <li>Acuco (ZA);</li>\n      <li>Alcorim-F (IN);</li>\n      <li>Anitrim (MX);</li>\n      <li>Avlotrin (BD);</li>\n      <li>Bacdan (TW);</li>\n      <li>Bacin (MY, SG, TH);</li>\n      <li>Bactelan (MX);</li>\n      <li>Bacteric (MX);</li>\n      <li>Bacterol (CL);</li>\n      <li>Bacterol Forte (CL);</li>\n      <li>Bacticel (AR);</li>\n      <li>Bactiver (MX);</li>\n      <li>Bactoprim (TH);</li>\n      <li>Bactramin (JP);</li>\n      <li>Bactrim (AE, AR, AT, AU, BB, BE, BH, BR, CH, CY, CZ, DE, DK, EC, EE, EG, FR, IN, IQ, IR, IT, JO, KW, LB, LV, LY, MT, MX, NO, OM, PK, PL, PT, QA, SA, SE, SK, SY, TH, TR, VN, YE);</li>\n      <li>Bactrim DS (AU, BB);</li>\n      <li>Bactrim F (CO);</li>\n      <li>Bactrim Forte (AT, FI, FR, LU, PH, PT, SE);</li>\n      <li>Bactrimel (GR, VE);</li>\n      <li>Bactropin (MX);</li>\n      <li>Baktrym (UA);</li>\n      <li>Biseptol (BG, LV, UA);</li>\n      <li>Brogamax (MX);</li>\n      <li>Co-Try (BD);</li>\n      <li>Colizole (IN);</li>\n      <li>Colizole DS (IN);</li>\n      <li>Cotrim (BF, BJ, CI, ET, GH, GM, GN, KE, KR, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Cotrim DS (MY);</li>\n      <li>Cotrimel (HK);</li>\n      <li>Cotrix (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Cotrizol (TW);</li>\n      <li>Deprim (MT);</li>\n      <li>Dhatrim (MY);</li>\n      <li>Dibaprim (MX);</li>\n      <li>Diseptyl (IL);</li>\n      <li>Duocide (TW);</li>\n      <li>Duratrimet (DE);</li>\n      <li>Ectaprim (MX);</li>\n      <li>Epitrim (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, RO, SA, SY, YE);</li>\n      <li>Escoprim (CH);</li>\n      <li>Espectrin (BR);</li>\n      <li>Eusaprim (AT, BE, FI, IS, IT, NO, SE);</li>\n      <li>Farcotrim (QA);</li>\n      <li>Fectrim (GB);</li>\n      <li>Gantaprim (IT);</li>\n      <li>Gantrim (IT);</li>\n      <li>Ikaprim (ID);</li>\n      <li>Infectrim (PE);</li>\n      <li>Introcin (CL);</li>\n      <li>Isotrim (IT);</li>\n      <li>Kepinol (DE);</li>\n      <li>Lagatrim (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Lagatrim Forte (BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LB, LR, MA, ML, MR, MU, MW, NE, NG, NL, PR, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);</li>\n      <li>Lidaprim (AE, SA);</li>\n      <li>Lidaprim Forte (AE, AT, SA);</li>\n      <li>Mano-Trim (TH);</li>\n      <li>Mano-Trim Forte (TH);</li>\n      <li>Medixin (IT);</li>\n      <li>Metoxiprim (MX);</li>\n      <li>Metrim (TH);</li>\n      <li>Microtrim (DE);</li>\n      <li>Morbifurb (CN);</li>\n      <li>Mortin (VN);</li>\n      <li>Nopil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Octex (MX);</li>\n      <li>Omsat (BF, BJ, CI, DE, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Oriprim (RU);</li>\n      <li>Oriprim DS (KE, TZ, UG, ZW);</li>\n      <li>Oxaprim (IT);</li>\n      <li>Politrim (BD);</li>\n      <li>Primzole (SG);</li>\n      <li>Purbal (ZA);</li>\n      <li>Resprim (AU);</li>\n      <li>Resprim Forte (AU);</li>\n      <li>Sanprima (ID);</li>\n      <li>Sanprima Forte (ID);</li>\n      <li>Septran (IN, PK, PY);</li>\n      <li>Septran Forte (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Septrin (AE, AU, BF, BH, BJ, CI, CY, EG, ES, ET, GB, GH, GM, GN, ID, IE, IQ, IR, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, OM, PE, PH, QA, SA, SC, SD, SG, SL, SN, SY, TN, TZ, UG, VN, YE, ZM, ZW);</li>\n      <li>Septrin DS (HK);</li>\n      <li>Septrin Forte (AU);</li>\n      <li>Servitrim (MX);</li>\n      <li>Sevatrim (KR);</li>\n      <li>Sigaprim (DE);</li>\n      <li>Sinersul (HR);</li>\n      <li>Soltrim (MX);</li>\n      <li>Suftrex (EC);</li>\n      <li>Sulfacet (DE);</li>\n      <li>Sulfoid Trimetho (MX);</li>\n      <li>Sulfotrimin (DE);</li>\n      <li>Sulotrim (HR);</li>\n      <li>Suntrim (TH);</li>\n      <li>Suntrim Forte (TH);</li>\n      <li>Suprim (PE);</li>\n      <li>Suprin (IT);</li>\n      <li>Tagremin (RO);</li>\n      <li>Timexole (MX);</li>\n      <li>TMS (DE);</li>\n      <li>Trim (IT, ZA);</li>\n      <li>Trimaxazole (SG);</li>\n      <li>Trimetoger (MX);</li>\n      <li>Trimexan (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Trimexazol (MX);</li>\n      <li>Trimexazole (TH);</li>\n      <li>Trimezol (BG);</li>\n      <li>Trimoprim (HK);</li>\n      <li>Trimox (TW);</li>\n      <li>Trimoxis (PH);</li>\n      <li>Triomax (JO);</li>\n      <li>Trisolvat (CO);</li>\n      <li>Trisul (BD, NZ);</li>\n      <li>Trizole (PH);</li>\n      <li>Tryseptol (UA);</li>\n      <li>Xepaprim (ID);</li>\n      <li>Xepaprim Forte (ID);</li>\n      <li>Zoltrim (EC);</li>\n      <li>Zultrop (ID);</li>\n      <li>Zultrop Forte (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agha R, Goldberg MB. Shigella infection: treatment and prevention in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alexander BD, Fishman JA. Prophylaxis of infections in solid organ transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alvarez RF, Mattos AA, Corr&ecirc;a EB, Cotrim HP, Nascimento TV. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. <i>Arq Gastroenterol</i>. 2005;42(4):256-262.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/16444382/pubmed\" target=\"_blank\" id=\"16444382\">16444382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Subcommittee on Urinary Tract Infection. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics. </i>2011;128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice, &quot;ACOG Committee Opinion No. 494: Sulfonamides, Nitrofurantoin, and Risk of Birth Defects,&quot; <i>Obstet Gynecol</i>, 2011, 117(6):1484-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/21606771/pubmed\" target=\"_blank\" id=\"21606771\">21606771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amin K, Riddle CC, Aires DJ, Schweiger ES. Common and alternate oral antibiotic therapies for acne vulgaris: a review. <i>J Drugs Dermatol</i>. 2007;6(9):873-880.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/17941358/pubmed\" target=\"_blank\" id=\"17941358\">17941358</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. <i>BMJ</i>. 2011;343.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/21911446/pubmed\" target=\"_blank\" id=\"21911446\">21911446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. <i>CMAJ</i>. 2015;187(4):E138-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/25646289/pubmed\" target=\"_blank\" id=\"25646289\">25646289</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. <i>Arch Intern Med</i>. 2010;170(12):1045-1049.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/20585070/pubmed\" target=\"_blank\" id=\"20585070\">20585070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ashkenazi S, Amir J, Waisman Y, et al, &quot;A Randomized, Double-Blind Study Comparing Cefixime and Trimethoprim-Sulfamethoxazole in the Treatment of Childhood Shigellosis,&quot; <i>J Pediatr</i>, 1993, 123(5):817-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/8229498/pubmed\" target=\"_blank\" id=\"8229498\">8229498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bactrim (sulfamethoxazole and trimethoprim) injection [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bartlett JG, Sethi S. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. <i>Drug Saf</i>. 2014;37(9):677-692.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/25047526/pubmed\" target=\"_blank\" id=\"25047526\">25047526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari E, Baddour LM. Prosthetic joint infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 12, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bissuel F, Cotte L, Crapanne JB, et al, &ldquo;Trimethoprim-Sulphamethoxazole Rechallenge in 20 Previously Allergic HIV-Infected Patients After Homeopathic,&rdquo; <i>AIDS</i>, 1995, 9(4):407-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7794554/pubmed\" target=\"_blank\" id=\"7794554\">7794554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/15303450/pubmed\" target=\"_blank\" id=\"15303450\">15303450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,&quot; MMWR Recomm Rep, 2009, 58(RR-11):1-166. Available at http://www.antimicrobe.org/h04c.files/history/CDC-HIV%20ExposeInfectChildren-2009.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2010,&rdquo; Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Surveillance Report for 2014 (Final Report). Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Diagnosis and Management of Q Fever - United States, 2013: Recommendations from CDC and the Q Fever Working Group,&quot; [published correction appears in MMWR Recomm Rep, 2013, 62(35):730]. <i>MMWR Recomm Rep</i>, 2013, 62(RR-03):1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/23535757/pubmed\" target=\"_blank\" id=\"23535757\">23535757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Treatment for cyclosporiasis. 2017. Available at <a href=\"https://www.cdc.gov/parasites/cyclosporiasis/health_professionals/tx.html\" target=\"_blank\">https://www.cdc.gov/parasites/</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC); DPDx - Laboratory Identification of Parasitic Diseases of Public Health Concern. Cystoisosporiasis. 2017. Available at <a href=\"https://www.cdc.gov/dpdx/cystoisosporiasis/tx.html\" target=\"_blank\">https://www.cdc.gov/parasites/cystoisospora/</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Laboratory diagnostics and treatment of nocardiosis. 2017. Available at <a href=\"https://www.cdc.gov/nocardiosis/health-care-workers/laboratory-diagnostics.html\" target=\"_blank\">https://www.cdc.gov/nocardiosis/</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/23535757/pubmed\" target=\"_blank\" id=\"23535757\">23535757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheng AC, McBryde ES, Wuthiekanun V, et al. Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis. <i>Antimicrob Agents Chemother.</i> 2009;53(10):4193-4199. doi: 10.1128/AAC.01301-08.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/19620336/pubmed\" target=\"_blank\" id=\"19620336\">19620336</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choo V, &ldquo;UK Revises Indications for Co-Trimoxazole,&rdquo; <i>Lancet</i>, 1995, 346(8968):175.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cockerill FR and Edson RS, &ldquo;Trimethoprim-Sulfamethoxazole,&rdquo; <i>Mayo Clin Proc</i>, 1991, 66(12):1260-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/1749295/pubmed\" target=\"_blank\" id=\"1749295\">1749295</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cook DE and Ponte CD, &ldquo;Suspected Trimethoprim/Sulfamethoxazole-Induced Hypoprothrombinemia,&rdquo; <i>J Fam Pract</i>, 1994, 39(6):589-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7798864/pubmed\" target=\"_blank\" id=\"7798864\">7798864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17966006\"></a>Cordero-Ampuero J, Esteban J, Garcia-Cimbrelo E, et al. &ldquo;Low Relapse With Oral Antibiotics and Two-Stage Exchange for Late Arthroplasty Infections in 40 Patients After 2-9 Years,&rdquo; <i>Acta Orthopaedica</i>, 2007, 78(4):511-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/17966006/pubmed\" target=\"_blank\" id=\"17966006\">17966006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crider KS, Cleves MA, Reefhuis J, et al, &quot;Antibacterial Medication Use During Pregnancy and Risk of Birth Defects: National Birth Defects Prevention Study,&quot; <i>Arch Pediatr Adolesc Med</i>, 2009, 163(11):978-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/19884587/pubmed\" target=\"_blank\" id=\"19884587\">19884587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czeizel AE, Rockenbauer M, S&oslash;rensen HT, et al, &quot;The Teratogenic Risk of Trimethoprim-Sulfonamides: A Population Based Case-Control Study,&quot; <i>Reprod Toxicol</i>, 2001, 15(6):637-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/11738517/pubmed\" target=\"_blank\" id=\"11738517\">11738517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dawkins B, Albury D, and Olsen TE, &ldquo;Trimethoprim/Sulfamethoxazole-Induced Thrombocytopenia - A Case Report Supported by the Laboratory Diagnosis,&rdquo; <i>Aust N Z J Med</i>, 1995, 25:83.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Della-Giustina K and Chow G, &quot;Medications in Pregnancy and Lactation,&quot; <i>Emerg Med Clin North Am</i>, 2003, 21(3):585-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/12962348/pubmed\" target=\"_blank\" id=\"12962348\">12962348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Domingo P, Ferrer S, Cruz J, et al, &ldquo;Trimethoprim-Sulfamethoxazole-Induced Renal Tubular Acidosis in a Patient With AIDS,&rdquo; <i>Clin Infect Dis</i>, 1995, 20(5):143, 45-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7727640/pubmed\" target=\"_blank\" id=\"7727640\">7727640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eleftheriadou I, Tentolouris N, Argiana V, Jude E, Boulton AJ. Methicillin-resistant Staphylococcus aureus in diabetic foot infections. <i>Drugs</i>. 2010;70(14):1785-1797.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/20836573/pubmed\" target=\"_blank\" id=\"20836573\">20836573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fischl MA, Dickinson GM, and La Voie L, &ldquo;Safety and Efficacy of Sulfamethoxazole and Trimethoprim Chemoprophylaxis for <i>Pneumocystis carinii</i> Pneumonia in AIDS,&rdquo; <i>JAMA</i>, 1988, 259(8):1185-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/3257532/pubmed\" target=\"_blank\" id=\"3257532\">3257532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. <i>Clin Infect Dis.</i> 2001;33(8):1397-1405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/11565082/pubmed\" target=\"_blank\" id=\"11565082\">11565082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. <i>Ann Pharmacother.</i> 2013;47(12):1618-1626. doi: 10.1177/1060028013509973.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/24259630/pubmed\" target=\"_blank\" id=\"24259630\">24259630</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2017 report. Available at http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golightly LK, Teitelbaum I, Kiser TH, et al. (eds.) <i>Renal Pharmacotherapy</i>. Springer Science, New York. 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.<i> Clin Infect Dis.</i> 2011;52(5):e103-120. doi: 10.1093/cid/ciq257.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/21292654/pubmed\" target=\"_blank\" id=\"21292654\">21292654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Harper M. Clinical manifestations and initial management of animal and human bites. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hennessy S, Strom BL, Berlin JA, et al, &ldquo;Predicting Cutaneous Hypersensitivity Reactions to Co-Trimoxazole in HIV-Infected Individuals Receiving Primary <i>Pneumocystis carinii</i> Pneumonia Prophylaxis,&rdquo; <i>J Gen Intern Med</i>, 1995, 10(7):380-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7472686/pubmed\" target=\"_blank\" id=\"7472686\">7472686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hern&aacute;ndez-D&iacute;az S and Mitchell AA, Author reply, <i>NEJM</i>, 2001, 344(12): 934-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hern&aacute;ndez-D&iacute;az S, Werler MM, Walker AM, et al, &quot;Folic Acid Antagonists During Pregnancy and the Risk of Birth Defects,&quot; <i>N Engl J Med</i>, 2000, 343(22):1608-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/11096168/pubmed\" target=\"_blank\" id=\"11096168\">11096168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections (OIs) in HIV-Exposed and HIV-Infected Children. December 2016. Available at <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2017. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed August 28, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hipolito RB, Mallorca FG, Zuniga-Macaraig ZO, Apolinario PC, Wheeler-Sherman J. Head lice infestation: single drug versus combination therapy with one percent permethrin and trimethoprim/sulfamethoxazole. <i>Pediatrics</i>. 2001;107(3):E30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/11230611/pubmed\" target=\"_blank\" id=\"11230611\">11230611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7885125\"></a>Hoge CW, Shlim DR, Ghimire M, et al. Placebo-controlled trial of co-trimoxazole for cyclospora infections among travellers and foreign residents in Nepal. <i>Lancet.</i> 1995;345(8951):691-693. Erratum in: <i>Lancet.</i> 1995;345(8956):1060.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7885125/pubmed\" target=\"_blank\" id=\"7885125\">7885125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hooton TM, Gupta K. Acute complicated cystitis and pyelonephritis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoppu K, &quot;Age Differences in Trimethoprim Pharmacokinetics: Need for Revised Dosing in Children?&quot; <i>Clin Pharmacol Ther</i>, 1987, 41(3):336-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/3816021/pubmed\" target=\"_blank\" id=\"3816021\">3816021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes W, Leoung G, Kramer F, et al, &ldquo;Comparison of Atovaquone (566C80) With Trimethoprim-Sulfamethoxazole to Treat <i>Pneumocystis carinii</i> Pneumonia in Patients With AIDS,&rdquo; <i>N Engl J Med</i>, 1993, 328(21):1521-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/8479489/pubmed\" target=\"_blank\" id=\"8479489\">8479489</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jick H and Derby LE, &ldquo;A Large Population-Based Follow-Up Study of Trimethoprim-Sulfamethoxazole, Trimethoprim, and Cephalexin for Uncommon Serious Drug Toxicity,&rdquo; <i>Pharmacotherapy</i>, 1995, 15(4):428-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7479194/pubmed\" target=\"_blank\" id=\"7479194\">7479194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jick H and Derby LE, &ldquo;Is Co-Trimoxazole Safe?&rdquo; <i>Lancet</i>, 1995, 345(8957):1118-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7715367/pubmed\" target=\"_blank\" id=\"7715367\">7715367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/15644481/pubmed\" target=\"_blank\" id=\"15644481\">15644481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lalani T. Overview of osteomyelitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leder K. Management of cystoisospora (isospora) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee M, Bozzo P, Einarson A, et al, &quot;Urinary Tract Infections in Pregnancy,&quot; <i>Can Fam Physician</i>, 2008, 54(6):853-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/18556490/pubmed\" target=\"_blank\" id=\"18556490\">18556490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8783685\"></a>Lerner PI. Nocardiosis. <i>Clin Infect Dis.</i> 1996;22(6):891-903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/8783685/pubmed\" target=\"_blank\" id=\"8783685\">8783685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis SS, Zaas A. Stenotrophomonas maltophilia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics.</i> 2013;131(3):e964-999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Limper AH, Knox KS, Sarosi GA, et al; American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.<i> Am J Respir Crit Care Med.</i> 2011;183(1):96-128. doi: 10.1164/rccm.2008-740ST.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/21193785/pubmed\" target=\"_blank\" id=\"21193785\">21193785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23171644\"></a>Lipsitz R, Garges S, Aurigemma R, et al. Workshop on treatment of and postexposure prophylaxis for <i>Burkholderia pseudomallei</i> and <i>B. mallei</i> Infection, 2010. <i>Emerg Infect Dis</i>. 2012;18(12):e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/23171644/pubmed\" target=\"_blank\" id=\"23171644\">23171644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA. Medical treatment of diabetic foot infections. <i>Clin Infect Dis</i>. 2004;39 Suppl 2:S104-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/15306988/pubmed\" target=\"_blank\" id=\"15306988\">15306988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis.</i> 2012;54(12):e132-e173. doi: 10.1093/cid/cis346.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Peters EJ, Senneville E, et al Expert opinion on the management of infections in the diabetic foot. <i>Diabetes Metab Res Rev.</i> 2012;28 Suppl 1:163-178. doi: 10.1002/dmrr.2248.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/22271739/pubmed\" target=\"_blank\" id=\"22271739\">22271739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. <i>Clin Infect Dis</i>. 2011;52(3):e18-e55. doi: 10.1093/cid/ciq146.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/21208910/pubmed\" target=\"_blank\" id=\"21208910\">21208910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19393961\"></a>Looney WJ, Narita M, and Muhlemann K. <i>Stenotrophomonas maltophilia</i>: an emerging opportunist human pathogen. <i>Lancet Infect Dis.</i> 2009;9(5):312-323. doi: 10.1016/S1473-3099(09)70083-0.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/19393961/pubmed\" target=\"_blank\" id=\"19393961\">19393961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lontos S, Shelton E, Angus PW, et al. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. <i>J Dig Dis</i>. 2014;15(5):260-267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/24612987/pubmed\" target=\"_blank\" id=\"24612987\">24612987</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lundstrom TS and Sobel JD, &ldquo;Vancomycin, Trimethoprim-Sulfamethoxazole, and Rifampin,&rdquo; <i>Infect Dis Clin North Am</i>, 1995, 9(3):747-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7490442/pubmed\" target=\"_blank\" id=\"7490442\">7490442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. <i>Am J Transplant.</i> 2013;13 Suppl 4:272-279. doi: 10.1111/ajt.12119.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/23465020/pubmed\" target=\"_blank\" id=\"23465020\">23465020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Masur MD, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-Infected persons &ndash; 2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. Ann Intern Med. 2002;137(5 Pt 2):435-478.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/12617574/pubmed\" target=\"_blank\" id=\"12617574\">12617574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matok I, Gorodischer R, Koren G, et al, &quot;Exposure to Folic Acid Antagonists During the First Trimester of Pregnancy and the Risk of Major Malformations,&quot;<i> Br J Clin Pharmacol</i>, 2009, 68(6):956-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/20002091/pubmed\" target=\"_blank\" id=\"20002091\">20002091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mattoo TK. Medical management of vesicoureteral reflux - quiz within the article. Don't overlook placebos. <i>Pediatr Nephrol.</i> 2007;22(8):1113-1120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/17483966/pubmed\" target=\"_blank\" id=\"17483966\">17483966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, Salter AJ. The passage of trimethoprim/sulfamethoxazole into breast milk and its significance. Proceedings of the 8th international congress of chemotherapy, Athens. Hellenic Soc Chemother 1974;1:687-691.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mitrano JA, Spooner LM, Belliveau P. Excretion of antimicrobials used to treat methicillin-resistant <i>Staphylococcus aureus</i> infections during lactation: safety in breastfeeding infants. <i>Pharmacotherapy</i>. 2009;29(9):1103-1109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/19698015/pubmed\" target=\"_blank\" id=\"19698015\">19698015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center.<i> Clin Infect Dis.</i> 2001;33(5):629-640.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/11486285/pubmed\" target=\"_blank\" id=\"11486285\">11486285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naber K, Vergin H, and Weigand W, &ldquo;Pharmacokinetics of Co-trimoxazole and Co-tetroxazine in Geriatric Patients,&rdquo; <i>Infection</i>, 1981, 9(5):239-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/6975241/pubmed\" target=\"_blank\" id=\"6975241\">6975241</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumann S, Krause SW, Maschmeyer G, et al; Infectious Diseases Working Party (AGIHO); German Society of Hematology and Oncology (DGHO). Primary prophylaxis of bacterial infections and pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Ann Hematol.</i> 2013;92(4):433-442. doi: 10.1007/s00277-013-1698-0.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/23412562/pubmed\" target=\"_blank\" id=\"23412562\">23412562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Noto H, Kaneko Y, Takano T, et al, &ldquo;Severe Hyponatremia and Hyperkalemia Induced by Trimethoprim-Sulfamethoxazole in Patients With <i>Pneumocystis carinii</i> Pneumonia,&rdquo; <i>Intern Med</i>, 1995, 34(2):96-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7727887/pubmed\" target=\"_blank\" id=\"7727887\">7727887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, Kirk O, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count &lt;200 cells/microL? <i>Clin Infect Dis.</i> 2010;51(5):611-619. Erratum in: <i>Clin Infect Dis.</i> 2010;51(9):1114. doi: 10.1086/655761.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/20645862/pubmed\" target=\"_blank\" id=\"20645862\">20645862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palmer SM, Zaas A, Wolfe C. Fungal infections following lung transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7944073\"></a>Pape JW, Verdier RI, Boncy M, et al, &ldquo;Cyclospora Infection in Adults Infected with HIV. Clinical Manifestations, treatment, and Prophylaxis,&rdquo; <i>Ann Intern Med</i>, 1994, 121(9):654-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7944073/pubmed\" target=\"_blank\" id=\"7944073\">7944073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. <i>Drug Saf</i>. 2000;22(3):227-236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/10738846/pubmed\" target=\"_blank\" id=\"10738846\">10738846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Practice Parameter: The Diagnosis, Treatment, and Evaluation of the Initial Urinary Tract Infection in Febrile Infants and Young Children. American Academy of Pediatrics, Committee on Quality Improvement, Subcommittee on Urinary Tract Infection,&rdquo; <i>Pediatrics</i>, 1999, 103(4 Pt 1):843-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/10103321/pubmed\" target=\"_blank\" id=\"10103321\">10103321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Red Book: 2009 Report of the Committee on Infectious Diseases</i>, 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. Alexandria, VA: American Association for the Study of Liver Diseases; 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed May 12, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA. Spontaneous bacterial peritonitis in adults: treatment and prophylaxis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sattler FR, Cowan R, Nielsen DM, et al, &ldquo;Trimethoprim-Sulfamethoxazole Compared With Pentamidine for Treatment of <i>Pneumocystis carinii</i> Pneumonia in the Acquired Immunodeficiency Syndrome,&rdquo; <i>Ann Intern Med</i>, 1988, 109(4):280-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/3260759/pubmed\" target=\"_blank\" id=\"3260759\">3260759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sax PE. Treatment and prevention of pneumocystis infection in HIV-infected patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Septra (sulfamethoxazole/trimethoprim) [product monograph]. Toronto, Ontario, Canada: Aspen Pharmacare Canada; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shiferaw B, Solghan S, Palmer A, et al. Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000-2010.<i> Clin Infect Dis.</i> 2012;54 Suppl 5:S458-463. doi: 10.1093/cid/cis230.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/22572670/pubmed\" target=\"_blank\" id=\"22572670\">22572670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sim S, Lee IY, Lee KJ, et al. A survey on head lice infestation in Korea (2001) and the therapeutic efficacy of oral trimethoprim/sulfamethoxazole adding to lindane shampoo. <i>Korean J Parasitol</i>. 2003;41(1):57-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/12666731/pubmed\" target=\"_blank\" id=\"12666731\">12666731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh N, Gayowski T, Yu VL, et al, &ldquo;Trimethoprim-Sulfamethoxazole for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhosis: A Randomized Trial,&rdquo; <i>Ann Intern Med</i>, 1995, 122(8):595-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7887554/pubmed\" target=\"_blank\" id=\"7887554\">7887554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/15242722/pubmed\" target=\"_blank\" id=\"15242722\">15242722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Snow V, Lascher S, Mottur-Pilson C; Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. <i>Ann Intern Med.</i> 2001;134(7):595-599.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/11281744/pubmed\" target=\"_blank\" id=\"11281744\">11281744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spelman D. Treatment of nocardiosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Springer C, Eyal F, and Michel J, &quot;Pharmacology of Trimethoprim-Sulfamethoxazole in Newborn Infants,&quot; <i>J Pediatr</i>, 1982, 100(4):647-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/7062219/pubmed\" target=\"_blank\" id=\"7062219\">7062219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al, &ldquo;Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,&rdquo; <i>Clin Infect Dis</i>, 2005; 41(10):1373&ndash;406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/16231249/pubmed\" target=\"_blank\" id=\"16231249\">16231249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26899755\"></a>Syed Q, Hendler KT, Koncilja K. The impact of aging and medical status on dysgeusia. <i>Am J Med</i>. 2016;129(7):753.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/26899755/pubmed\" target=\"_blank\" id=\"26899755\">26899755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tan HH. Antibacterial therapy for acne: a guide to selection and use of systemic agents. <i>Am J Clin Dermatol</i>. 2003;4(5):307-314.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/12688836/pubmed\" target=\"_blank\" id=\"12688836\">12688836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas CF, Limper AH. Treatment and prevention of pneumocystis pneumonia in HIV-uninfected patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and MarrowTransplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant.</i> 2009;15(10):1143-1238. doi: 10.1016/j.bbmt.2009.06.019. Erratum in: <i>Biol Blood Marrow Transplant.</i> 2010;16(2):294. Boeckh, Michael A [corrected to Boeckh, Michael J].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/15373844/pubmed\" target=\"_blank\" id=\"15373844\">15373844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torre D, Casari S, Speranza F, et al, &ldquo;Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Pyrimethamine-Sulfadiazine for Therapy of Toxoplasmic Encephalitis in Patients With AIDS. Italian Collaborative Study Group,&rdquo; <i>Antimicrob Agents Chemother</i>, 1998, 42(6):1346-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/9624473/pubmed\" target=\"_blank\" id=\"9624473\">9624473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis.</i> 2004;39(9):1267-1284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varoquaux O, Lajoie D, Gobert C, et al, &ldquo;Pharmacokinetics of the Trimethoprim-Sulfamethoxazole Combination in the Elderly,&rdquo; <i>Br J Clin Pharmacol</i>, 1985, 20(6):575-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/3879182/pubmed\" target=\"_blank\" id=\"3879182\">3879182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vartivarian S, Anaissie E, Bodey G, et al, &quot;A Changing Pattern of Susceptibility of <i>Xanthomonas maltophilia</i> to Antimicrobial Agents: Implications for Therapy,&quot; <i>Antimicrob Agents Chemother</i>, 1994, 38(3):624-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/8203865/pubmed\" target=\"_blank\" id=\"8203865\">8203865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients. <i>Paediatr Drugs</i>. 2004;6(1):45-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/14969569/pubmed\" target=\"_blank\" id=\"14969569\">14969569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verdier RI, Fritzgerald DW, Johnson WD, et al, &ldquo; Trimethoprim-Sulfamethoxazole Compared With Ciprofloxacin for Treatment and Prophylaxis of <i>Isospora belli</i> and <i>Cyclospora cayetanensis</i> Infection in HIV-Infected Patients,&rdquo; <i>Ann Intern Med</i>, 2000, 132(11):885-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/10836915/pubmed\" target=\"_blank\" id=\"10836915\">10836915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24145530\"></a>Wang YL, Scipione MR, Dubrovskaya Y, et al. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of stenotrophomonas maltophilia infections. <i>Antimicrob Agents Chemother.</i> 2014;58(1):176-182. doi: 10.1128/AAC.01324-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/24145530/pubmed\" target=\"_blank\" id=\"24145530\">24145530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24008153\"></a>Wang HK, Sheng WH, Hung CC, et al. Clinical characteristics, microbiology, and outcomes for patients with lung and disseminated nocardiosis in a tertiary hospital.<i> J Formos Med Assoc.</i> 2015;114(8):742-749. doi: 10.1016/j.jfma.2013.07.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/24008153/pubmed\" target=\"_blank\" id=\"24008153\">24008153</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weller PF, Leder K. Cyclospora infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wood GC, Underwood EL, Croce MA, et al, &quot;Treatment of Recurrent <i>Stenotrophomonas maltophilia</i> Ventilator-Associated Pneumonia With Doxycycline and Aerosolized Colistin,&quot; <i>Ann Pharmacother</i>, 2010, 44(10):1665-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/20736426/pubmed\" target=\"_blank\" id=\"20736426\">20736426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &ldquo;Guidelines for the Control of Shigellosis, Including Epidemics Due to Shigella dysenteriae Type 1&rdquo;, 2005. Available at http://whqlibdoc.who.int/publications/2005/9241592330.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ylikorkala O, Sj&ouml;stedt E, J&auml;rvinen PA, et al, &quot;Trimethoprim-Sulfonamide Combination Administered Orally and Intravaginally in the First Trimester of Pregnancy: Its Absorption Into Serum and Transfer to Amniotic Fluid,&quot; <i>Acta Obstet Gynecol Scand</i>, 1973, 52(3):229-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/4743777/pubmed\" target=\"_blank\" id=\"4743777\">4743777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed May 17, 2016.26897386</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. <i>Int Arch Allergy Immunol</i>. 2010;153(2):152-156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information/abstract-text/20413982/pubmed\" target=\"_blank\" id=\"20413982\">20413982</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9785 Version 239.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F154885\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F154886\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F154907\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F154889\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F154900\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F154890\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F154891\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22757570\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F154857\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F154842\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F45703744\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50148639\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F154861\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F154860\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470631\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F154917\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F154849\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F154864\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F154846\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F154902\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F154851\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F154854\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F154867\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F154868\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F154869\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6059143\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F154845\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F154863\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F154866\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F154870\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9785|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-patient-drug-information\" class=\"drug drug_patient\">Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information</a></li><li><a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information</a></li></ul></div></div>","javascript":null}